MiR-125a-3p and miR-320b differentially expressed in patients with chronic myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation and imatinib mesylate

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorMartins, Juliana R. B.-
Autor(es): dc.creatorMoraes, Leonardo N.-
Autor(es): dc.creatorCury, Sarah S.-
Autor(es): dc.creatorCapannacci, Juliana-
Autor(es): dc.creatorCarvalho, Robson Francisco-
Autor(es): dc.creatorNogueira, Célia Regina-
Autor(es): dc.creatorHokama, Newton Key-
Autor(es): dc.creatorHokama, Paula O. M.-
Data de aceite: dc.date.accessioned2025-08-21T22:45:22Z-
Data de disponibilização: dc.date.available2025-08-21T22:45:22Z-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2021-10-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3390/ijms221910216-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/229567-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/229567-
Descrição: dc.descriptionChronic myeloid leukemia (CML), a hematopoietic neoplasm arising from the fusion of BCR (breakpoint cluster region) gene on chromosome 22 to the ABL (Abelson leukemia virus) gene on chromosome 9 (BCR-ABL1 oncogene), originates from a small population of leukemic stem cells with extensive capacity for self-renewal and an inflammatory microenvironment. Currently, CML treatment is based on tyrosine kinase inhibitors (TKIs). However, allogeneic hematopoietic stem cell transplantation (HSCT-allo) is currently the only effective treatment of CML. The difficulty of finding a compatible donor and high rates of morbidity and mortality limit transplantation treatment. Despite the safety and efficacy of TKIs, patients can develop resistance. Thus, microRNAs (miRNAs) play a prominent role as biomarkers and post-transcriptional regulators of gene expression. The aim of this study was to analyze the miRNA profile in CML patients who achieved cytogenetic remission after treatment with both HSCT-allo and TKI. Expression analyses of the 758 miRNAs were performed using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Bioinformatics tools were used for data analysis. We detected miRNA profiles using their possible target genes and target pathways. MiR-125a-3p stood out among the downregulated miRNAs, showing an interaction network with 52 target genes. MiR-320b was the only upregulated miRNA, with an interaction network of 26 genes. The results are expected to aid future studies of miRNAs, residual leukemic cells, and prognosis in CML.-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionDepartment of Internal Medicine Botucatu Medical School São Paulo State University (FMB-UNESP)-
Descrição: dc.descriptionDepartment of Bioprocesses and Biotechnology School of Agriculture São Paulo State University (FCA-UNESP)-
Descrição: dc.descriptionDepartment of Structural and Functional Biology Institute of Biosciences São Paulo State University (IBB-UNESP)-
Descrição: dc.descriptionDepartment of Internal Medicine Botucatu Medical School São Paulo State University (FMB-UNESP)-
Descrição: dc.descriptionDepartment of Bioprocesses and Biotechnology School of Agriculture São Paulo State University (FCA-UNESP)-
Descrição: dc.descriptionDepartment of Structural and Functional Biology Institute of Biosciences São Paulo State University (IBB-UNESP)-
Descrição: dc.descriptionFAPESP: 11/50629-7-
Idioma: dc.languageen-
Relação: dc.relationInternational Journal of Molecular Sciences-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectAllogeneic hematopoietic stem cell transplantation-
Palavras-chave: dc.subjectChronic myeloid leukemia-
Palavras-chave: dc.subjectImatinib mesylate-
Palavras-chave: dc.subjectMiR-125a-3p-
Palavras-chave: dc.subjectMiR-320b-
Palavras-chave: dc.subjectMiRNAs-
Título: dc.titleMiR-125a-3p and miR-320b differentially expressed in patients with chronic myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation and imatinib mesylate-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.